Ribon Therapeutics and Pfizer have entered into an agreement to leverage Pfizer's global development expertise and capabilities to support the advancement of Ribon's pipeline. Ribon will retain economic rights and control of clinical development across all its programs.
Market Closed -
Other stock markets
|
After market 21:26:18 | |||
27.81 USD | +0.40% | 27.8 | -0.02% |
11:17am | GSK plc : Back on track | |
12:23am | Wall Street: optimism ahead of NFP, rates ease | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.40% | 157B | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
+8.10% | 149B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Ribon Therapeutics and Pfizer Have Enter into an Agreement